Mesenchymal Stem Cell Exosomes Regulate ILK Pathway

The patent extracts the therapeutic function from the entire cell and isolates it into exosomes. By separating and using only the essential functional components (exosomes containing miRNAs and proteins) rather than whole cells, the therapy achieves therapeutic effects while eliminating the harmful immunogenicity and tumorigenicity associated with cell transplantation.

Exosomes serve as an intermediary carrier that delivers therapeutic molecules to target cells. Instead of directly transplanting cells that would trigger immune responses, the patent uses exosomes as a mediator to transfer functional miRNAs and proteins, achieving therapy without direct cell contact and thus avoiding immunogenicity and tumorigenicity.

The patent segments the complex stem cell system into distinct functional components: exosomes as the delivery vehicle, miRNAs as the regulatory molecules, and ILK pathway members as the targets. This segmentation allows systematic investigation of each component's role, gradually elucidating the mechanism of action while maintaining the observed therapeutic effects on tissue repair and angiogenesis.

The patent employs feedback mechanisms by detecting and measuring the expression levels of ILK pathway members and other relevant genes before and after exosome treatment. This feedback information is used to validate the therapeutic effects and refine the understanding of the mechanism of action, creating a iterative process that clarifies pathway involvement while maintaining reliable tissue repair and angiogenesis promotion.